Abstract
In December 2004, pegaptanib sodium (Macugen; Eyetech/Pfizer), which targets vascular endothelial growth factor, was approved by the US FDA for the treatment of neovascular age-related macular degeneration. As well as being the first anti-angiogenic agent to be approved for this common eye disorder, it is also the first approved therapeutic based on an RNA structure known as an aptamer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Diabetic angiopathy and angiogenic defects
Fibrogenesis & Tissue Repair Open Access 01 August 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Congdon, N. et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122, 477–485 (2004).
Fine, S. L. et al. Age-related macular degeneration. N. Engl. J. Med. 342, 483–492 (2000).
Clark, A. F. & Yorio, T. Ophthalmic drug discovery. Nature Rev. Drug Discov. 2, 448–459 (2003).
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).
Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480–1487 (1994).
Ruckman, J. et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556–20567 (1998).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/021756lbl.pdf> (2004).
Gragoudas, E. S. et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004).
Age-Related Eye Diseases Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch. Ophthalmol. 119, 1417–1436 (2001).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Fine, S., Martin, D. & Kirkpatrick, P. Pegaptanib sodium. Nat Rev Drug Discov 4, 187–188 (2005). https://doi.org/10.1038/nrd1677
Issue Date:
DOI: https://doi.org/10.1038/nrd1677
This article is cited by
-
Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis
Graefe's Archive for Clinical and Experimental Ophthalmology (2014)
-
Diabetic angiopathy and angiogenic defects
Fibrogenesis & Tissue Repair (2012)
-
Ranibizumab
Nature Reviews Drug Discovery (2006)